Concise review: Genetically engineered stem cell therapy targeting angiogenesis and tumor stroma in gastrointestinal malignancy

Stem Cells

Volumn 31, Issue 2, 2013, Pages 227-235

  Keung, Emily Z ^a   Nelson, Peter J ^b   Conrad, Claudius ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF MUNICH   (Germany)

Author keywords

Angiogenesis; Gastrointestinal malignancy; Gene therapy; Genetic engineering; Mesenchymal stem cell; Stroma

Indexed keywords

5' NUCLEOTIDASE; ENDOGLIN; GANCICLOVIR; PRODRUG; RANTES; SECONDARY LYMPHOID TISSUE CHEMOKINE; SITIMAGENE CERADENOVEC; THY 1 ANTIGEN; TUMOR MARKER; VIRUS VECTOR;

ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; CANCER GENE THERAPY; CANCER INHIBITION; CARCINOGENESIS; CELL HOMING; CYTOKINE RELEASE; ENDOTHELIAL PROGENITOR CELL; GASTROINTESTINAL STROMAL TUMOR; GENE DELIVERY SYSTEM; GENE EXPRESSION REGULATION; GENETIC ENGINEERING; LIVER CELL CARCINOMA; MESENCHYMAL STEM CELL TRANSPLANTATION; MOUSE; NONHUMAN; PANCREAS ADENOCARCINOMA; REVIEW; SUICIDE GENE THERAPY; SUICIDE TRANSGENE; TARGET ORGAN; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION; TUMOR XENOGRAFT;

ADENOCARCINOMA; CARCINOMA, HEPATOCELLULAR; CELL DIFFERENTIATION; CELL ENGINEERING; GENES, TRANSGENIC, SUICIDE; GENETIC THERAPY; HUMANS; LIVER NEOPLASMS; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; MULTIPOTENT STEM CELLS; NEOVASCULARIZATION, PATHOLOGIC; PANCREATIC NEOPLASMS; STROMAL CELLS;

EID: 84874317309     PISSN: 10665099     EISSN: None     Source Type: Journal    
DOI: 10.1002/stem.1269     Document Type: Review

References (81)

1. Howlader N, Noone AM, Krapcho M et al. eds. SEER Cancer Statistics Review, 1975-200-8. Bethesda, MD: National Cancer Institute, 201-1. Available at: http://seer.cancer.gov/csr/1975-2008/, based on November 2010 SEER data submission, posted to the SEER web site, 201-1.
2. Shah K. Mesenchymal stem cells engineered for cancer therapy. Adv Drug Deliv Rev 2012;64:739;74-8.
3. Green MR. Targeting targeted therapy. N Engl J Med 2004;350:2191; 219-3.
4. Corsten MF, Shah K. Therapeutic stem-cells for cancer treatment: Hopes and hurdles in tactical warfare. Lancet Oncol 2008;9:376;38-4.
5. Yip S, Shah K. Stem-cell based therapies for brain tumors. Curr Opin Mol Ther 2008;10:334;34-2.
6. Cihova M, Altanerova V, Altaner C. Stem cell based cancer gene therapy. Mol Pharm 2011;8:1480;148-7.
7. Klopp AH, Spaeth EL, Dembinski JL et al. Tumor irradiation increases the recruitment of circulating mesenchymal stem cells into the tumor microenvironment. Cancer Res 2007;67:11687; 1169-5.
8. Sagar J, Chaib B, Sales K et al. Role of stem cells in cancer therapy and cancer stem cells: A review. Cancer Cell Int 2007;7:-9.
9. Spring H, Schuler T, Arnold B et al. Chemokines direct endothelial progenitors into tumor neovessels. Proc Natl Acad Sci USA 2005;102: 18111;1811-6. (Pubitemid 41798510)
10. Studeny M, Marini FC, Champlin RE et al. Bone marrow-derived mesenchymal stem cells as vehicles for interferon-beta delivery into tumors. Cancer Res 2002;62:3603;360-8.
11. Studeny M, Marini FC, Dembinski JL et al. Mesenchymal stem cells: Potential precursors for tumor stroma and targeted-delivery vehicles for anticancer agents. J Natl Cancer Inst 2004;96:1593;160-3.
12. Hodgkinson CP, Gomez JA, Mirotsou M et al. Genetic engineering of mesenchymal stem cells and its application in human disease therapy. Hum Gene Ther 2010;21:1513;152-6.
13. Kim SU, Jeung EB, Kim YB et al. Potential tumor-tropic effect of genetically engineered stem cells expressing suicide enzymes to selectively target invasive cancer in animal models. Anticancer Res 2011;31:1249;125-8.
14. Dwyer RM, Khan S, Barry FP et al. Advances in mesenchymal stem cell-mediated gene therapy for cancer. Stem Cell Res Ther 2010;1: 2-5.
15. Chamberlain G, Fox J, Ashton B et al. Concise review: Mesenchymal stem cells: Their phenotype, differentiation capacity, immunological features, and potential for homing. Stem Cells 2007;25:2739; 274-9.
16. Altaner C. Prodrug cancer gene therapy. Cancer Lett 2008;270:191; 20-1.
17. Kern S, Eichler H, Stoeve J et al. Comparative analysis of mesenchymal stem cells from bone marrow, umbilical cord blood, or adipose tissue. Stem Cells 2006;24:1294;130-1.
18. Conrad C, Gupta R, Mohan H et al. Genetically engineered stem cells for therapeutic gene delivery. Curr Gene Ther 2007;7:249;26-0.
19. Kerbel RS. Tumor angiogenesis. N Engl J Med 2008;358:2039;204-9.
20. Huang H, Bhat A, Woodnutt G et al. Targeting the ANGPT-TIE2 pathway in malignancy. Nat Rev Cancer 2010;10:575;58-5.
21. Mazzieri R, Pucci F, Moi D et al. Targeting the ANG2/TIE2 axis inhibits tumor growth and metastasis by impairing angiogenesis and disabling rebounds of proangiogenic myeloid cells. Cancer Cell 2011; 19:512;52-6.
22. Fox JM, Chamberlain G, Ashton BA et al. Recent advances into the understanding of mesenchymal stem cell trafficking. Br J Haematol 2007;137:491;50-2.
23. Karp JM, Leng Teo GS. Mesenchymal stem cell homing: The devil is in the details. Cell Stem Cell 2009;4:206;21-6.
24. Mishra PJ, Humeniuk R, Medina DJ et al. Carcinoma-associated fibroblast- like differentiation of human mesenchymal stem cells. Cancer Res 2008;68:4331;433-9.
25. Gao D, Nolan D, McDonnell K et al. Bone marrow-derived endothelial progenitor cells contribute to the angiogenic switch in tumor growth and metastatic progression. Biochim Biophys Acta 2009;1796: 33;4-0.
26. Beckermann BM, Kallifatidis G, Groth A et al. VEGF expression by mesenchymal stem cells contributes to angiogenesis in pancreatic carcinoma. Br J Cancer 2008;99:622;63-1.
27. Lyden D, Hattori K, Dias S et al. Impaired recruitment of bone-marrow- derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat Med 2001;7:1194;120-1.
28. Azenshtein E, Luboshits G, Shina S et al. The CC chemokine RANTES in breast carcinoma progression: Regulation of expression and potential mechanisms of promalignant activity. Cancer Res 2002; 62:1093;110-2.
29. Soria G, Ben-Baruch A. The inflammatory chemokines CCL2 and CCL5 in breast cancer. Cancer Lett 2008;267:271;28-5.
30. Andoh A, Takaya H, Saotome T et al. Cytokine regulation of chemokine (IL-8, MCP-1, And Rantes) gene expression in human pancreatic periacinar myofibroblasts. Gastroenterology 2000;119:211;21-9.
31. Jin H, Aiyer A, Su J et al. A homing mechanism for bone marrowderived progenitor cell recruitment to the neovasculature. J Clin Invest 2006;116:652;66-2.
32. Ruster B, Gottig S, Ludwig RJ et al. Mesenchymal stem cells display coordinated rolling and adhesion behavior on endothelial cells. Blood 2006;108:3938;394-4. (Pubitemid 44864580)
33. Shinagawa K, Kitadai Y, Tanaka M et al. Mesenchymal stem cells enhance growth and metastasis of colon cancer. Int J Cancer 2010; 127:2323;233-3.
34. Oswald J, Boxberger S, Jorgensen B et al. Mesenchymal stem cells can be differentiated into endothelial cells in vitro. Stem Cells 2004; 22:377;38-4.
35. Mishra PJ, Glod JW, Banerjee D. Mesenchymal stem cells: Flip side of the coin. Cancer Res 2009;69:1255;125-8.
36. De Palma M, Venneri MA, Galli R et al. Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors. Cancer Cell 2005;8:211;22-6.
37. Folkman J. Tumor angiogenesis: Therapeutic implications. N Engl J Med 1971;285:1182;118-6.
38. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996;86:353;36-4.
39. Bhowmick NA, Neilson EG, Moses HL. Stromal fibroblasts in cancer initiation and progression. Nature 2004;432:332;33-7.
40. Hammerling GJ, Ganss R. Vascular integration of endothelial progenitors during multistep tumor progression. Cell Cycle 2006;5: 509;51-1.
41. Karnoub AE, Dash AB, Vo AP et al. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 2007;449: 557;56-3. (Pubitemid 47525152)
42. Francois S, Bensidhoum M, Mouiseddine M et al. Local irradiation not only induces homing of human mesenchymal stem cells at exposed sites but promotes their widespread engraftment to multiple organs: A study of their quantitative distribution after irradiation damage. Stem Cells 2006;24:1020;1029. (Pubitemid 44464735)
43. Friedman EJ. Immune modulation by ionizing radiation and its implications for cancer immunotherapy. Curr Pharm Des 2002;8:1765; 178-0. (Pubitemid 34846202)
44. Hahn JY, Cho HJ, Kang HJ et al. Pre-treatment of mesenchymal stem cells with a combination of growth factors enhances gap junction formation, cytoprotective effect on cardiomyocytes, and therapeutic efficacy for myocardial infarction. J Am Coll Cardiol 2008;51:933; 94-3.
45. Lu G, Haider HK, Jiang S et al. Sca-1 stem cell survival and engraftment in the infarcted heart: Dual role for preconditioninginduced connexin-4-3. Circulation 2009;119:2587;259-6.
46. Rosova I, Dao M, Capoccia B et al. Hypoxic preconditioning results in increased motility and improved therapeutic potential of human mesenchymal stem cells. Stem Cells 2008;26:2173;218-2.
47. Shi M, Li J, Liao L et al. Regulation of CXCR4 expression in human mesenchymal stem cells by cytokine treatment: Role in homing efficiency in NOD/SCID mice. Haematologica 2007;92:897;90-4. (Pubitemid 350144236)
48. Wynn RF, Hart CA, Corradi-Perini C et al. A small proportion of mesenchymal stem cells strongly expresses functionally active CXCR4 receptor capable of promoting migration to bone marrow. Blood 2004;104:2643;264-5. (Pubitemid 39434942)
49. Bhakta S, Hong P, Koc O. The surface adhesion molecule CXCR4 stimulates mesenchymal stem cell migration to stromal cell-derived factor-1 in vitro but does not decrease apoptosis under serum deprivation. Cardiovasc Revasc Med 2006;7:19;2-4.
50. Cheng Z, Ou L, Zhou X et al. Targeted migration of mesenchymal stem cells modified with CXCR4 gene to infarcted myocardium improves cardiac performance. Mol Ther 2008;16:571;57-9. (Pubitemid 351314998)
51. Wisel S, Khan M, Kuppusamy ML et al. Pharmacological preconditioning of mesenchymal stem cells with trimetazidine (1- [l2,3,4-trimethoxybenzyl] piperazine) protects hypoxic cells against oxidative stress and enhances recovery of myocardial function in infarcted heart through Bcl-2 expression. J Pharmacol Exp Ther 2009; 329:543;55-0.
52. Zhang D, Fan GC, Zhou X et al. Over-expression of CXCR4 on mesenchymal stem cells augments myoangiogenesis in the infarcted myocardium. J Mol Cell Cardiol 2008;44:281;29-2.
53. Zhao T, Zhang D, Millard RW et al. Stem cell homing and angiomyogenesis in transplanted hearts are enhanced by combined intramyocardial SDF-1alpha delivery and endogenous cytokine signaling. Am J Physiol Heart Circ Physiol 2009;296: H976;98-6.
54. Guo X, Evans TR, Somanath S et al. In vitro evaluation of cancerspecific NF-kappaB-CEA enhancer-promoter system for 5-fluorouracil prodrug gene therapy in colon cancer cell lines. Br J Cancer 2007;97: 745;75-4. (Pubitemid 47396284)
55. Nyati MK, Sreekumar A, Li S et al. High and selective expression of yeast cytosine deaminase under a carcinoembryonic antigen promoterenhancer. Cancer Res 2002;62:2337;234-2. (Pubitemid 34411714)
56. Conrad C, Husemann Y, Niess H et al. Linking transgene expression of engineered mesenchymal stem cells and angiopoietin-1-induced differentiation to target cancer angiogenesis. Ann Surg 2011;253:566; 57-1.
57. De Palma M, Mazzieri R, Politi LS et al. Tumor-targeted interferonalpha delivery by Tie2-expressing monocytes inhibits tumor growth and metastasis. Cancer Cell 2008;14:299;31-1.
58. De Palma M, Venneri MA, Roca C et al. Targeting exogenous genes to tumor angiogenesis by transplantation of genetically modified hematopoietic stem cells. Nat Med 2003;9:789;79-5. (Pubitemid 36749231)
59. Niess H, Bao Q, Conrad C et al. Selective targeting of genetically engineered mesenchymal stem cells to tumor stroma microenvironments using tissue-specific suicide gene expression suppresses growth of hepatocellular carcinoma. Ann Surg 2011;254:767;77-5.
60. Herbst RS, Hong D, Chap L et al. Safety, pharmacokinetics, and antitumor activity of AMG 386, a selective angiopoietin inhibitor, in adult patients with advanced solid tumors. J Clin Oncol 2009;27: 3557;356-5.
61. Orimo A, Gupta PB, Sgroi DC et al. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 2005;121: 335;34-8. (Pubitemid 40692295)
62. De Wever O, Mareel M. Role of tissue stroma in cancer cell invasion. J Pathol 2003;200:429;44-7. (Pubitemid 36818244)
63. Kiaris H, Trimis G, Papavassiliou AG. Regulation of tumor-stromal fibroblast interactions: Implications in anticancer therapy. Curr Med Chem 2008;15:3062;306-7.
64. Hung SC, Deng WP, Yang WK et al. Mesenchymal stem cell targeting of microscopic tumors and tumor stroma development monitored by noninvasive in vivo positron emission tomography imaging. Clin Cancer Res 2005;11:7749;775-6. (Pubitemid 41611618)
65. Zischek C, Niess H, Ischenko I et al. Targeting tumor stroma using engineered mesenchymal stem cells reduces the growth of pancreatic carcinoma. Ann Surg 2009;250:747;75-3.
66. Mohr A, Albarenque SM, Deedigan L et al. Targeting of XIAP combined with systemic mesenchymal stem cell-mediated delivery of sTRAIL ligand inhibits metastatic growth of pancreatic carcinoma cells. Stem Cells 2010;28:2109;212-0.
67. Menon LG, Kelly K, Yang HW et al. Human bone marrow-derived mesenchymal stromal cells expressing S-TRAIL as a cellular delivery vehicle for human glioma therapy. Stem Cells 2009;27:2320; 233-0.
68. Sasportas LS, Kasmieh R, Wakimoto H et al. Assessment of therapeutic efficacy and fate of engineered human mesenchymal stem cells for cancer therapy. Proc Natl Acad Sci USA 2009;106:4822;482-7.
69. Yang B, Wu X, Mao Y et al. Dual-targeted antitumor effects against brainstem glioma by intravenous delivery of tumor necrosis factorrelated, apoptosis-inducing, ligand-engineered human mesenchymal stem cells. Neurosurgery 2009; 65:610-624; discussion 62-4.
70. Luetzkendorf J, Mueller LP, Mueller T et al. Growth inhibition of colorectal carcinoma by lentiviral TRAIL-transgenic human mesenchymal stem cells requires their substantial intratumoral presence. J Cell Mol Med 2010;14:2292;230-4.
71. Vogler M, Durr K, Jovanovic M et al. Regulation of TRAIL-induced apoptosis by XIAP in pancreatic carcinoma cells. Oncogene 2007;26: 248;25-7. (Pubitemid 46095735)
72. Vogler M, Walczak H, Stadel D et al. Small molecule XIAP inhibitors enhance TRAIL-induced apoptosis and antitumor activity in preclinical models of pancreatic carcinoma. Cancer Res 2009;69: 2425;243-4.
73. Vogler M, Walczak H, Stadel D et al. Targeting XIAP bypasses Bcl-2-mediated resistance to TRAIL and cooperates with TRAIL to suppress pancreatic cancer growth in vitro and in vivo. Cancer Res 2008;68:7956;796-5.
74. Fillat C, Carrio M, Cascante A et al. Suicide gene therapy mediated by the Herpes Simplex virus thymidine kinase gene/Ganciclovir system: Fifteen years of application. Curr Gene Ther 2003;3:13;2-6.
75. Portsmouth D, Hlavaty J, Renner M. Suicide genes for cancer therapy. Mol Aspects Med 2007;28:4;4-1.
76. Kucerova L, Altanerova V, Matuskova M et al. Adipose tissue-derived human mesenchymal stem cells mediated prodrug cancer gene therapy. Cancer Res 2007;67:6304;631-3. (Pubitemid 47037513)
77. Dwyer RM, Ryan J, Havelin RJ et al. Mesenchymal stem cell-mediated delivery of the sodium iodide symporter supports radionuclide imaging and treatment of breast cancer. Stem Cells 2011;29:1149; 115-7.
78. Knoop K, Kolokythas M, Klutz K et al. Image-guided, tumor stromatargeted 131I therapy of hepatocellular cancer after systemic mesenchymal stem cell-mediated NIS gene delivery. Mol Ther 2011;19: 1704;171-3.
79. Djouad F, Bony C, Apparailly F et al. Earlier onset of syngeneic tumors in the presence of mesenchymal stem cells. Transplantation 2006;82:1060;106-6. (Pubitemid 44632122)
80. Djouad F, Plence P, Bony C et al. Immunosuppressive effect of mesenchymal stem cells favors tumor growth in allogeneic animals. Blood 2003;102:3837;384-4. (Pubitemid 37409409)
81. Naldini L. Ex vivo gene transfer and correction for cell-based therapies. Nat Rev Genet 2011;12:301;31-5.